Want to Subscribe?
Read Corporate India and add to your Business Intelligence

Unlock Unlimited Access
Published: February 28, 2025
Updated: February 28, 2025
BSE ticker code | 506401 |
NSE ticker code | DEEPAKNTR |
Major activity | Speciality Chemicals |
CMD | Deepak C. Mehta |
Equity capital | Rs 27.28 crore; FV Rs 02 |
52 week high/low | Rs 3169 / Rs 1810 |
CMP | Rs 1922.75 |
Market Capitalisation | Rs 26224.97 crore |
Recommendation | Buy |
Headquartered at Vadodara (Gujarat), Deepak Nitrite Ltd (DNL) is a multi-division and multi product chemical intermediates manufacturer engaged in manufacturing chemical intermediaries, fine and speciality chemicals, products and phenolics. It has a wide portfolio of over 100 products, with leader ship in the majority of its products. The company’s manufacturing fa cilities are located at Nandesari and Dahej in Gujarat, Roha and Taloja in Maharashtra, and Hyderabad in Telangana.
Deepak Nitrite’s products have several use cases, such as in colourants, petrochemicals, rubbers, adhesives, personal care, thinners, ply, laminates and foundry. The com pany enjoys a 75 per cent marketshare in sodium nitrite and nitrotoluenes in India. It also has an over 50 per cent marketshare in phenol and acetone. It can boast of over 1,000 customers in India as well as in Europe, the US, Asia and the Middle East.
The company has made rapid strides on the financial front, with its sales turnover during the last 10 years ex panding almost six times from Rs 1,327 crore in fiscal 2015 to Rs 7,682 crore in fiscal 2024, operating profit shooting up around eight times from Rs 140 crore to Rs 1,127 crore, and the profit at net level surging over 15 times from Rs 53 crore to Rs 811 crore. However, as with other chemical companies, Deepak’s sales and earnings have been adversely affected in the recent downturn. But it is widely believed that the downward drift will not per sist for a long time and the revival will began within the next few years. Consider:
PERFORMANCE INDICATORS (Rs. in crore)
Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
---|---|---|---|---|---|
2023-24 | 7681.83 | 727.65 | 53.30 | 375.00 | 373.10 |
2024-25 (E) | 7840.50 | 780.15 | 54.70 | 375.00 | 380.40 |
2025-26 (E) | 8139.17 | 825.40 | 57.10 | 385.00 | 385.29 |
BSE ticker code | 540975 |
NSE ticker code | ASTERDM |
Major activity | Hospital |
Chairman | Mandayapurath Azadmoopen |
Equity capital | Rs 499.51 crore; FV Rs 10 |
52 week high/low | Rs 559 / Rs 312 |
CMP | Rs 410.45 |
Market Capitalisation | Rs 20502.51 crore |
Recommendation | Buy |
Aster DM Healthcare is one of the largest integrated healthcare service providers in the Middle East and an emerging player in India. It has op erations in seven countries, including GCC and India. Its integrated model covers the entire life cycle of healthcare — from primary to quaternary — through its state-of-the art hospitals, clinics and pharma ceuticals. The company is focused on expansion via an asset-light model (1,000 beds through O&M) in India. The management is tar geting an India expansion with low capex investment but high poten tial opportunity.
Aster’s network consists of 13 hospitals, 109 clinics and 240 retail pharmacies in the GCC states, and 14 hospitals, 11 clinics, 131 phar macies and 141 laboratories in In dia, with total bed capacity being 460 in GCC and 3,905 in India.
The company is doing quite well on the financial front. During the last 12 years, sales have almost doubled from Rs 7,922 crore in fiscal 2013 to Rs 3,699 crore in fiscal 2024, with operating profit more than doubling from Rs 261 crore to Rs 575 crore, and the profit at net level inching up from Rs 149 crore to Rs 212 crore. What is more, prospects for the company going ahead are all the more promising. Con sider:
PERFORMANCE INDICATORS (Rs. in crore)
Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
---|---|---|---|---|---|
2023-24 | 3698.90 | 125.84 | 2.50 | 20.00 | 60.40 |
2024-25 (E) | 3850.40 | 128.40 | 2.65 | 20.00 | 62.75 |
2025-26 (E) | 4160.40 | 135.54 | 2.85 | 25.00 | 66.46 |
BSE ticker code | 544117 |
NSE ticker code | SIGNPOST |
Major activity | Advertising & Media Agencies |
Chairman | Girish Pandurang Kulkarni |
Equity capital | Rs 10.69 crore; FV Rs 02 |
52 week high/low | Rs 461 / Rs 212 |
CMP | Rs 251.95 |
Market Capitalisation | Rs 1346.67 crore |
Recommendation | Buy |
Mumbai-headquartered Signpost India is a small cap player providing both static and digital OOH (out of house) advertising services. Since inception in 2008, it has emerged as a leading outdoor advertising solutions provider that cre ates advertising properties around public convenience utili ties, including airports, metros, bus shelters and city roads, and uses them for display of advertisements through design, technology, data analytics and content provision. With demon strable experience, the company engi neers end-to-end mega projects to build public places that ensure com muters’ convenience, ergonomic and transparent roofing and priority seat ing, tactile flooring, accessibility ramp, charging stations, SOS integration, mapped surrounding lavatories, au thority notifications of upcoming buses, and much more. The company has re ceived awards in numerous categories, including 57 gold, 43 silver and 28 bronze, including prestigious ones like ABBYs, ENVIEs, Lon don Digital Signage, and Kyoorius Dragon of Asia.
Signpost has clients in multiple industries, including con sumer goods and services, BFSI, lifestyle, real estate and con struction, media, entertainment, education, pharma, telecom, automobiles and hospitality, as well as in government minis tries.
It has steadily grown on the financial front since incep tion in 2008 and after its listing in 2021. During the last three years (after it got listed on BSE and NSE), revenues have expanded from Rs 168 crore in fiscal 2022 to Rs 338 crore in fiscal 2023 and further to Rs 387 crore in fiscal 2024, with the profit at net level shooting up from Rs 8 crore in fiscal 2022 to Rs 3 crore in fiscal 2023 and further to Rs 44 crore in fiscal 2024. Signpst’s financial position is very strong, with reserves at the end of March 2024 standing at Rs 205 crore — over 18 times its tiny equity capital of Rs 11 crore. What is more, prospects going ahead are all the more promising. Consider:
PERFORMANCE INDICATORS (Rs. in crore)
Year | Net Series | Net Profit | EPS (Rs.) | Div (%) | BV (%) |
---|---|---|---|---|---|
2023-24 | 387.45 | 41.20 | 7.70 | 25.00 | 40.40 |
2024-25 (E) | 405.45 | 42.40 | 7.90 | 25.00 | 41.50 |
2025-26 (E) | 424.50 | 40.70 | 8.45 | 30.00 | 43.70 |
March 15, 2025 - First Issue
Industry Review
Want to Subscribe?
Read Corporate India and add to your Business Intelligence
Unlock Unlimited Access
Lighter Vein
Popular Stories
Archives